Online inquiry

IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ598MR)

This product GTTS-WQ598MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Spinal cord injury research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ598MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7685MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ3133MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ7578MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ688MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ5817MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ3557MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ6233MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW